drugset / Trial / NCT00005617
Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma
Treatment
Summary
RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have stage IV, or relapsed malignant melanoma.
Timeline
- Start
- 1997-07
- Primary completion
- 2002-06
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | dendritic cell-MART-1 peptide vaccine | Vaccine | 100000 cells | Intravenous |
| Subject | dendritic cell-MART-1 peptide vaccine | Vaccine | 1e+06 cells | Intravenous |
| Subject | dendritic cell-MART-1 peptide vaccine | Vaccine | 1e+07 cells | Intravenous |